Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

Current Medical Research and Opinion

Volumn 24, Issue 12, 2008, Pages 3559-3569

  Muszbek, Noemi ^a   Shah, Sonalee ^b   Carroll, Stuart ^a   McDonald, Heather ^c   Dale, Peter ^a   Maroun, Jean ^d   Knox, Jennifer ^e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BAYER CORPORATION   (United States)

^c Bayer Inc   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Hepatocellular carcinoma; Modeling; Sorafenib

Indexed keywords

PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANADA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; MALE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT; DISEASE FREE SURVIVAL; ECONOMICS; EUROPE; LIVER TUMOR; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SURVIVAL RATE; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CANADA; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; EUROPE; HUMANS; LIVER NEOPLASMS; MARKOV CHAINS; MODELS, THEORETICAL; PYRIDINES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 57749196018     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802563706     Document Type: Article

References (55)

1. El-Serag HB, Rudolph L. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 2007;132:2557-2576
2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6
3. GLOBOCAN 2002, IARC http://www-dep.iarc.fr/(accessed on 22nd September, 2005)
4. Dyer Z, Peltekian K, van Zanten SV. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 2005;22:17-22
5. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995;109:917-922
6. Group C. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998;352:17-20
7. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-394
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442
9. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58
10. Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-417
11. GRETCH. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamozifen. Hepatology 2004;40:1361-1369
12. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-1161
13. Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598-1600
14. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991
15. Falkson G, Moertel CG, Lavin P, et al. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978;42:2149-2156
16. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983;51:206-210
17. Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984;53:401-405
18. Falkson G, MacIntyre JM, Moertel CG, et al. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1984;54:970-977
19. Falkson G, MacIntyre JM, Schutt AJ, et al. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 1984;2:581-584
20. Bezwoda WR, Weaving A, Kew M, et al. Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin+VM 26+5-fluorouracil with mAMSA + VM 26+5-fluorouracil. Oncology 1987;44:207-209
21. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483
22. Falkson G, Cnaan A, Simson IW, et al. A randomized phase II study of acivicin and 40deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1990;13:510-515
23. Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:452-459
24. Yeo W, Zee B, Leung W, et al. A phase III study of doxorubicin versus PIAF for inoperable HCC. ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22:4026
25. Llovet JN. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized clinical trials. Alimen Pharmcol Ther 2006;23:1535-1547
26. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390
27. Health Canada: Drug Product Database. Available at http://www.hc-sc.gc. ca/dhp-mps/prodpharma/databasdon/index-eng.php (accessed August 9, 2007)
28. U.S. Food and Drug Administration: Center for Drug Evaluation and Research. Available at http://www.fda.gov/cder/index.html (accessed August 9, 2007)
29. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430
30. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236
31. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233-238
32. Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: Impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005;20:873-881
33. Perry JF, Charlton B, Koorey DJ, et al. Outcome of patients with hepatocellular carcinoma referred to a tertiary center with availability of multiple treatment options including cadaveric liver transplantation. Liver Int 2007;27:1240-1248
34. Butler SP, Morris DL, King J, et al. Survival in patients with hepatocellular carcinoma treated with intra-arterial I-131 labelled lipiodol. GI Cancer 2001;3:359-369
35. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917
36. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67
37. Cancer Institute NSW, DOH qtr Sep-07; MERU Reference: 08-1006 (unpublished)
38. Grusenmeyer PA, Wong YN. Interpreting the economic literature in oncology. J Clin Oncol 2007;2:196-202
39. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007;24:3603-3608
40. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007;6:625-633
41. Griffin S, Bojke L, Main C, et al. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer. Value Health 2006;2:123-131
42. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada, 3rd edn. Ottawa: The Agency, 2006. http://www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf
43. Gold MR, Siegel JE, Russell LB, et al., eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996
44. Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008;26:4509
45. Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press, 2003
46. Delta PA, Brogan Inc. https://baesecure.broganinc.com/BAEPRDAPP/dpa/ GridView.aspx (last accessed September, 2007)
47. Ontario Schedule of Benefits for Physician Services under the Health Insurance Act; http://www.health.gov.on.ca/english/providers/program/ohip/sob/ physserv/physserv-mn.html (last accessed Sept, 2007)
48. Hospital participating in the Ontario Case Costing Project. http://www.occp.com/, Ontario Schedule of Benefits for Insured Services (last accessed September, 2007)
49. British Columbia Medical Services Commission Payment Schedule; http://www.hlth.gov.bc.ca/msp/infoprac/physbilling/payschedule/index.html (last accessed September, 2007)
50. Costing obtained from University Health Network, Toronto. 2006
51. Ontario drug benefit formulary/comparative drug index [database online]. Toronto: Ministry of Health and Long Term Care; 2006. Available: http://www.health.gov.on.ca/english/providers/program/drugs/odbf-eformulary. html (last accessed September, 2007)
52. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-95
53. Rocchi A, Menon D, Verma S, et al. The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond. Value Health 2008;11:771-783
54. Canadian Agency forDrugs and Technologies inHealth (CADTH) CEDAC final recommendation and reasons for recommendation - Sunitinib malate (Accessed 10th December, 2007b) http://www.cadth.ca/media/cdr/complete/cdr-complete-Sutent-e- April-26-2007%20.pdf
55. Bukowsky R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;30:220-227